ADAA offers an annual award to an early career investigator for the best original research paper on neurobiology, psychopharmacology, psychosocial treatments, or experimental psychopathology of anxiety disorders and depression. This award is named for Donald F. Klein, MD (1928-2019), who revolutionized psychiatric thinking through his discovery in the early 1960s that imipramine, a recently developed psychotropic medication, was effective in blocking panic attacks.
The Donald F. Klein award is presented at ADAA's Annual Conference. This opportunity is open to members and nonmembers. Have a question email [email protected].
"The Donald F. Klein award offers a wonderful opportunity to highlight the work of promising young investigators and provides the logistical support for them to be able to share their work with the field more broadly. I am grateful for the opportunity to share my work with others and to have expanded my academic connections." Sage E. Hawn, PhD
- Complimentary registration to the ADAA Annual Conference (a $500 value)
- A $500 cash award
- Complimentary one year ADAA annual membership (up to $249 value)
- Award presented at the Annual Conference Award Ceremony on Saturday.
- Opportunity to present research as a poster at the ADAA Annual Conference.
- Selected paper will be seriously considered for publication with formal review in ADAA’s journal - Depression and Anxiety
- Featured profile on the ADAA website
- Restricted to investigators who have completed their terminal degree and are currently at a rank of assistant professor or below.
- Individuals who are working to complete their degree are not eligible.
- Willingness to host a professional webinar (recorded or live) within six months of winning the award on the research topic of the paper.
- Must be first or senior author on the submitted paper, which must be original research on anxiety disorders, depression, and comorbid related disorders, focusing on neurobiology, psychosocial treatments, or experimental psychopathology.
- The paper cannot be submitted or under review anywhere else from submission until notification about the award (including ADAA's Depression and Anxiety Journal).
- ADAA recognizes, supports, and values the inclusion of diverse groups, educational backgrounds, and views and encourages award applications from minority groups. ADAA also encourages interdisciplinary as well as international applicants.
- ADAA Board Members and Scientific Council members are not eligible.
Please note that the Klein award does not provide a travel or hotel allowance. ADAA strongly suggests awardees book their stay at the conference hotel.
Thank you to our Klein Award Reviewers: Naomi Simon, MD, Msc and Charles B. Nemeroff, MD, PhD
- View the 2021 Awardee and Runner-Up Research Feature Webinars: Annmarie MacNamara, PhD and Hilary Weingarden, PhD
About Donald F. Klein
This award is named for Donald F. Klein, MD (1928-2019), who revolutionized psychiatric thinking through his discovery in the early 1960s that imipramine, a recently developed psychotropic medication, was effective in blocking panic attacks. Dr. Klein’s early contribution to the development of the DSM in large part gave birth to the modern branch of medical science dealing with the classification of disease of anxiety disorders. His early findings also heralded in the era of childhood anxiety disorders as biochemical disorders when he discovered that imipramine blocked childhood separation anxiety disorders.
In later years, Dr. Klein developed a compelling evolutionary-based hypothesis accounting for the etiology of panic disorders, which he terms “the false suffocation alarm theory of panic disorders.” His work remains relevant and topical to the present. Dr. Klein was the recipient of the 2005 ADAA Lifetime Achievement Award.
The Donald F. Klein Early Career Investigator Award is supported by Depression and Anxiety, the official journal of ADAA, published by Wiley-Blackwell, the scientific, technical, medical, and scholarly business of John Wiley & Sons, Inc.